Abstract
Atopic dermatitis (AD) is a paradigmatic skin disease in which multiple gene-gene and gene-environment interactions play a pivotal role. Although the complex pathophysiologic network of AD explains the large spectrum of risk and trigger factors, it is far from being comprehensively understood. Hence, genetic modifications underlying the dysfunction of the epidermal skin barrier as well as the close interaction of innate and adaptive immune mechanisms were the focus of intensive research studies. This review aims to summarize the most recent findings in this field.
Similar content being viewed by others
References and Recommended Reading
Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al.: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441–446.
Baurecht H, Irvine AD, Novak N, et al.: Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007, 120:1406–1412.
Weidinger S, Illig T, Baurecht H, et al.: Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006, 118:214–219.
Weidinger S, Rodriguez E, Stahl C, et al.: Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 2007, 127:724–726.
Bisgaard H, Simpson A, Palmer CN, et al.: Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008, 5:e131.
Kezic S, Kemperman PM, Koster ES, et al.: Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol 2008, 128:2117–2119.
de Jongh CM, Khrenova L, Verberk MM, et al.: Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. Br J Dermatol 2008, 159:621–627.
Novak N, Baurecht H, Schafer T, et al.: Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008, 128:1430–1435.
Howell MD, Kim BE, Gao P, et al.: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007, 120:150–155.
Cookson W: The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004, 4:978–988.
Vasilopoulos Y, Cork MJ, Murphy R, et al.: Genetic association between an AACC insertion in the 3’UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol 2004, 123:62–66.
De Benedetto A, Latchney LE, McGirt LS, et al.: The tight junction protein Claudin-1 is dysregulated in atopic dermatitis. J Allergy Clin Immunol 2008, 121:S32.
Soderhall C, Marenholz I, Kerscher T, et al.: Variants in a novel epidermal collagen gene (COL29A1) are associated with atopic dermatitis. PLoS Biol 2007, 5:e242.
Esparza-Gordillo J, Weidinger S, Fölster-Holst R, et al.: A common variant on chromosome 11q13 is associated with atopic dermatitis. Nat Genet 2009, 41:596–601.
Hata TR, Gallo RL: Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg 2008, 27:144–150.
Maintz L, Novak N: Getting more and more complex: The pathophysiology of atopic eczema. Eur J Dermatol 2007, 17:267–283.
Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, et al.: The Toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004, 113:565–567.
Weidinger S, Novak N, Klopp N, et al.: Lack of association between Toll-like receptor 2 and Toll-like receptor 4 polymorphisms and atopic eczema. J Allergy Clin Immunol 2006, 118:277–279.
Niebuhr M, Langnickel J, Draing C, et al.: Dysregulation of Toll-like receptor-2 (TLR-2)-induced effects in monocytes from patients with atopic dermatitis: impact of the TLR-2 R753Q polymorphism. Allergy 2008, 63:728–734.
Novak N, Yu CF, Bussmann C, et al.: Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007, 62:766–772.
Howell MD: The role of human beta defensins and cathelicidins in atopic dermatitis. Curr Opin Allergy Clin Immunol 2007, 7:413–417.
Gläser R, Meyer-Hoffert U, Harder J, et al.: The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J Invest Dermatol 2009, 129:641–649.
Rieg S, Steffen H, Seeber S, et al.: Deficiency of dermcidinderived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol 2005, 174:8003–8010.
Hata TR, Kotol P, Jackson M, et al.: Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008, 122:829–831.
Yamasaki K, Schauber J, Coda A, et al.: Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006, 20:2068–2080.
Yamasaki K, Di NA, Bardan A, et al.: Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007, 13:975–980.
Soruri A, Grigat J, Forssmann U, et al.: beta-Defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol 2007, 37:2474–2486.
Grigat J, Soruri A, Forssmann U, et al.: Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human alpha-defensin family. J Immunol 2007, 179:3958–3965.
Esnault S, Rosenthal LA, Wang DS, Malter JS: Thymic stromal lymphopoietin (TSLP) as a bridge between infection and atopy. Int J Clin Exp Pathol 2008, 1:325–330.
Ebner S, Nguyen VA, Forstner M, et al.: Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007, 119:982–990.
Traidl-Hoffmann C, Mariani V, Hochrein H, et al.: Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005, 201:627–636.
Jin H, Oyoshi MK, Le Y, et al.: IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest 2009, 119:47–60.
Eyerich K, Pennino D, Scarponi C, et al.: IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009, 123:59.e4–66.e4.
He R, Oyoshi MK, Jin H, Geha RS: Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc Natl Acad Sci U S A 2007, 104:15817–15822.
Sonkoly E, Muller A, Lauerma AI, et al.: IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117:411–417.
Neis MM, Peters B, Dreuw A, et al.: Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006, 118:930–937.
Schulz F, Marenholz I, Folster-Holst R, et al.: A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 2007, 120:1097–1102.
Grimstad O, Sawanobori Y, Vestergaard C, et al.: Antiinterleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009, 18:35–43.
Illi S, von ME, Lau S, et al.: The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004, 113:925–931.
Bieber T: Atopic dermatitis. N Engl J Med 2008, 358:1483–1494.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bieber, T., Novak, N. Pathogenesis of atopic dermatitis: New developments. Curr Allergy Asthma Rep 9, 291–294 (2009). https://doi.org/10.1007/s11882-009-0041-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11882-009-0041-2